Debiopharm | GenomeWeb

Debiopharm

The firm said that it has completed clinical trials for the Group B Strep assay for the FDA and will start trials for the C. difficile test this month. 

The investment is the second for GenePOC from the Swiss pharmaceutical company, which will also now also manufacture GenePOC consumables in Europe.

Molecular diagnostic sample prep firm Spinomix has received an undisclosed payment from Swiss-based global biopharmaceutical conglomerate Debiopharm Group for achieving a development milestone for a pair of sample prep technologies, Debiopharm said this week.

WaferGen Biosystems has shuffled and reduced the size of its board of directors to seven from nine following the firm's acquisition of IntegenX's next-g

Swiss molecular diagnostics developer Diagnoplex said last week that it has closed a CHF1.3 million ($1.4 million) financing round led by Debiopharm Diagnostics, part of the Swiss-based global biopharmaceutical conglomerate Debiopharm Group.

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.

This article has been updated to include comment from Marina's management.

While a handful of pricey deals have dominated the headlines, a handful of other companies over the past year have formed more modest collaborations to see whether they can take advantage of RNAi as a therapeutic modality.

Under the terms of the deal, Debiopharm will have “full responsibility for the development and commercialization of any products arising from the partnership,” the companies said.

Pages

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.